Overview

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

Status:
Active, not recruiting
Trial end date:
2023-03-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and entering their first RSV season.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca